Capital Fund Management S.A. Purchases 76,015 Shares of Corcept Therapeutics Incorporated $CORT

Capital Fund Management S.A. raised its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 90.0% in the third quarter, Holdings Channel reports. The fund owned 160,444 shares of the biotechnology company’s stock after buying an additional 76,015 shares during the quarter. Capital Fund Management S.A.’s holdings in Corcept Therapeutics were worth $13,334,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Abacus FCF Advisors LLC bought a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $3,238,000. Pacer Advisors Inc. increased its position in Corcept Therapeutics by 6,796.7% in the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock worth $32,459,000 after buying an additional 384,896 shares during the period. Brown Capital Management LLC bought a new position in Corcept Therapeutics in the 3rd quarter worth approximately $19,950,000. Cerity Partners LLC lifted its holdings in shares of Corcept Therapeutics by 21.4% during the second quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock worth $54,800,000 after buying an additional 131,799 shares during the last quarter. Finally, Synergy Asset Management LLC lifted its holdings in shares of Corcept Therapeutics by 96.1% during the third quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company’s stock worth $39,615,000 after buying an additional 248,362 shares during the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CORT shares. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research note on Wednesday, December 31st. UBS Group initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. Finally, Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, January 23rd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Corcept Therapeutics has a consensus rating of “Hold” and a consensus target price of $77.17.

Corcept Therapeutics Stock Performance

CORT opened at $32.39 on Friday. The stock’s 50 day simple moving average is $37.87 and its 200-day simple moving average is $63.44. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.45 billion, a PE ratio of 39.50 and a beta of 0.29. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The firm had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same period last year, the business earned $0.26 earnings per share. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. Sell-side analysts forecast that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Insider Activity

In other news, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00. Following the completion of the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. This trade represents a 94.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 48,233 shares of company stock valued at $1,817,306. Corporate insiders own 20.80% of the company’s stock.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: H.C. Wainwright cut its price target on CORT from $67 to $60 but kept a Buy rating — a mixed signal that preserves analyst support while lowering upside expectations. H.C. Wainwright Cuts Price Target
• Neutral Sentiment: Short‑interest reporting in recent feeds shows anomalous/zero values (0 shares, NaN) and thus provides no clear indication of a coordinated short trade; treat these figures with caution until cleaner data is available.
• Negative Sentiment: Rosen Law Firm is soliciting Corcept investors to join the securities class action and warns of an April 21, 2026 lead‑plaintiff deadline — amplifying legal risk and potential settlement exposure. Rosen Law Firm Notice
• Negative Sentiment: Hagens Berman and several other plaintiff firms (Pomerantz, Bernstein Liebhard, Levi & Korsinsky, Glancy, Schall, DJS, Johnson Fistel, Kaplan Fox, etc.) have notified/investigated investors about the same securities claim — the proliferation of firms increases publicity and the likelihood of litigation costs or settlement activity. Hagens Berman Alert
• Negative Sentiment: Pomerantz and other firms are similarly urging affected investors to contact them ahead of the April 21 deadline, keeping the story in the headlines and pressuring sentiment. Pomerantz Notice

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.